These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706 [TBL] [Abstract][Full Text] [Related]
33. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells. Ribeiro M; Rosenstock TR; Oliveira AM; Oliveira CR; Rego AC Free Radic Biol Med; 2014 Sep; 74():129-44. PubMed ID: 24992836 [TBL] [Abstract][Full Text] [Related]
34. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. Brustovetsky N; LaFrance R; Purl KJ; Brustovetsky T; Keene CD; Low WC; Dubinsky JM J Neurochem; 2005 Jun; 93(6):1361-70. PubMed ID: 15935052 [TBL] [Abstract][Full Text] [Related]
35. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. Martín-Aparicio E; Yamamoto A; Hernández F; Hen R; Avila J; Lucas JJ J Neurosci; 2001 Nov; 21(22):8772-81. PubMed ID: 11698589 [TBL] [Abstract][Full Text] [Related]
36. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937 [TBL] [Abstract][Full Text] [Related]
37. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Reddy PH; Shirendeb UP Biochim Biophys Acta; 2012 Feb; 1822(2):101-10. PubMed ID: 22080977 [TBL] [Abstract][Full Text] [Related]
38. Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease. Siddiqui A; Rivera-Sánchez S; Castro Mdel R; Acevedo-Torres K; Rane A; Torres-Ramos CA; Nicholls DG; Andersen JK; Ayala-Torres S Free Radic Biol Med; 2012 Oct; 53(7):1478-88. PubMed ID: 22709585 [TBL] [Abstract][Full Text] [Related]
39. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573 [TBL] [Abstract][Full Text] [Related]
40. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Lu B; Al-Ramahi I; Valencia A; Wang Q; Berenshteyn F; Yang H; Gallego-Flores T; Ichcho S; Lacoste A; Hild M; Difiglia M; Botas J; Palacino J Nat Neurosci; 2013 May; 16(5):562-70. PubMed ID: 23525043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]